[SCHEDULE 13G/A] Inhibikase Therapeutics, Inc. Amended Passive Investment Disclosure
Perceptive reports 9.99% stake in Inhibikase
Perceptive Advisors LLC and its affiliates report beneficial ownership of 12,816,643 shares of Inhibikase Therapeutics common stock, representing 9.99% of the class.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Perceptive Advisors LLC and its affiliates report beneficial ownership of 12,816,643 shares of Inhibikase Therapeutics common stock, representing 9.99% of the class. This total includes shares underlying pre-funded and common warrants held by Perceptive Life Sciences Master Fund, Ltd., subject to a 9.99% ownership cap on warrant exercise.
The ownership percentage is based on 120,899,650 shares outstanding as of a recent prospectus supplement, and reflects shared voting and dispositive power among Perceptive Advisors, Joseph Edelman, and the Master Fund. The group certifies the holdings are not for the purpose of changing or influencing control of Inhibikase.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Perceptive Advisors report in Inhibikase Therapeutics (IKT)?
Perceptive Advisors and related reporting persons report beneficial ownership of 12,816,643 Inhibikase Therapeutics common shares, or 9.99% of the outstanding class. This figure combines directly held stock and warrants that are currently exercisable within a 9.99% ownership limit.
Which entities are reporting ownership of IKT in this Schedule 13G/A?
The filing lists three Reporting Persons: Perceptive Advisors LLC, its managing member Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. All three report the same 12,816,643 shares beneficially owned, with shared voting and dispositive power over the position.
How is Perceptive’s 9.99% ownership in IKT calculated?
The 9.99% stake is based on 120,899,650 outstanding IKT common shares, as cited from a recent prospectus supplement. It also assumes exercise of certain warrants up to 7,395,075 shares, subject to a contractual 9.99% beneficial ownership limitation on exercises.
What types of securities does Perceptive’s IKT position include?
Perceptive’s position includes 5,421,568 common shares and multiple warrant series: 790,000 pre-funded warrants at $0.001 per share and common warrants for 3,357,211 and 6,173,664 shares at higher exercise prices. Together they form the reported beneficial ownership amount.
Does Perceptive intend to influence control of Inhibikase Therapeutics (IKT)?
The reporting persons certify the securities were not acquired and are not held with the purpose or effect of changing or influencing control of Inhibikase. They also state the holdings are not in connection with any transaction aimed at obtaining such control.
Who directly holds the Inhibikase Therapeutics securities reported in this filing?
Perceptive Life Sciences Master Fund, Ltd. directly holds the IKT common shares and warrants. Perceptive Advisors acts as investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors, giving them shared voting and dispositive power.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
INHIBIKASE THERAPEUTICS, INC.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
45719W205
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
45719W205
1
Names of Reporting Persons
Perceptive Advisors LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
12,816,643.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
12,816,643.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
12,816,643.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
CUSIP No.
45719W205
1
Names of Reporting Persons
Joseph Edelman
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
12,816,643.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
12,816,643.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
12,816,643.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
CUSIP No.
45719W205
1
Names of Reporting Persons
Perceptive Life Sciences Master Fund, Ltd.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
12,816,643.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
12,816,643.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
12,816,643.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.99 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
INHIBIKASE THERAPEUTICS, INC.
(b)
Address of issuer's principal executive offices:
1000 N. West Street, Suite 1200, Wilmington, DE, 19801
Item 2.
(a)
Name of person filing:
The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.001 per share (the "Common Stock") of Inhibikase Therapeutics, Inc. (the "Issuer") are:
(i) Perceptive Advisors LLC ("Perceptive Advisors")
(ii) Joseph Edelman ("Mr. Edelman")
(iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is:
51 Astor Place, 10th Floor, New York, NY 10003
(c)
Citizenship:
Perceptive Advisors is a Delaware limited liability company.
Mr. Edelman is a United States citizen.
The Master Fund is a Cayman Islands corporation.
(d)
Title of class of securities:
Common Stock, $0.001 par value
(e)
CUSIP No.:
45719W205
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 120,899,650 outstanding shares of Common Stock, as reported by the Issuer in its prospectus supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on November 21, 2025, and assume the exercise of Warrants (as defined below) held by the Reporting Persons for 7,395,075 shares of Common Stock.
Neither Perceptive Advisors nor Mr. Edelman directly holds any Common Stock. The Master Fund directly holds (i) 5,421,568 shares of Common Stock, (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase 790,000 shares of Common Stock at an exercise price of $0.001 per share, (iii) common warrants to purchase 3,357,211 shares of Common Stock at an exercise price of $1.37 per share, and (iv) common warrants to purchase 6,173,664 shares of Common Stock at an exercise price of $1.49 per share (together with the Pre-Funded Warrants, the "Warrants"). The terms of the Warrants provide that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the shares of Common Stock then issued and outstanding. As of the date hereof, this limitation permits the Reporting Persons to exercise Warrants for up to 7,395,075 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors.
(b)
Percent of class:
Perceptive Advisors: 9.99%
Mr. Edelman: 9.99%
Master Fund: 9.99%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Perceptive Advisors: 0
Mr. Edelman: 0
Master Fund: 0
(ii) Shared power to vote or to direct the vote:
Perceptive Advisors: 12,816,643
Mr. Edelman: 12,816,643
Master Fund: 12,816,643
(iii) Sole power to dispose or to direct the disposition of:
Perceptive Advisors: 0
Mr. Edelman: 0
Master Fund: 0
(iv) Shared power to dispose or to direct the disposition of:
Perceptive Advisors: 12,816,643
Mr. Edelman: 12,816,643
Master Fund: 12,816,643
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
